Ultomiris® (ravulizumab-cwvz)

Ravulizumab-cwvz (Ultomiris™) is a humanized monoclonal antibody with a high affinity for C5, a protein in the complement cascade that is essential for the formation of the membrane attack complex responsible for cell lysis. Ravulizumab is a complement inhibitor Food and Drug Administration (FDA) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and for atypical uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients one month of age and older. Ravulizumab is also FDA-approved for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and for neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.